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Abstract
Disruption of chromatin structure due to epimutations is a leading genetic etiology of neurodevelopmental disorders,
collectively known as chromatinopathies. We show that there is an increasing level of convergence from the high diversity
of genes that are affected by mutations to the molecular networks and pathways involving the respective proteins, the
disrupted cellular and subcellular processes, and their consequence for higher order cellular network function. This
convergence is ultimately reflected by specific phenotypic features shared across the various chromatinopathies. Based on
these observations, we propose that the commonly disrupted molecular and cellular anomalies might provide a rational
target for the development of symptomatic interventions for defined groups of genetically distinct neurodevelopmental
disorders.
Introduction
Almost all cells in our body contain the same DNA, yet clearly a
large variety of different cell types can be distinguished by their
morphology, function and RNA expression profiles (1). The differ-
ences between these cell types are controlled by chemical modi-
fications and structural organization of the chromatin, popularly
alluded to as ‘epigenetic mechanisms’. Epigenetic modifications
guide the patterns of gene expression and are installed along
pre-defined developmental lineages from the zygote to the full
set of differentiated cells and organs (2). Such epigenetic modi-
fications can be transmitted between successive generations of
cells to maintain cell identity. In addition, epigenetic modifica-
tions can also be introduced by external triggers, e.g. exposure
to toxins, nutrients and stress, which can have life-long effects.
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Consequently, epigenetics is considered a rational mediator of
gene × environment interactions. Finally, epigenetic modifica-
tions are required for memory formation and other forms of
learning, suggesting that epigenetic modifications might act as
a cellular memory (3,4). In view of this, it is not surprising that
disruptions of the epigenetic machinery are often underlying
mental disorders alluded to as chromatinopathies (5).
Epimutations in genes causing
neurodevelopmental disorders
Our review is confined to monogenetic neurodevelopmental
disorders (NDDs) caused by highly penetrant secondary epimu-
tations causing cognitive impairment as the major and consis-
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of such disorders and respective genes carrying epimutations
(6–11). These overviews vary because of the rapid increase of
new NDD genes. In addition, the definition ‘epigenetic genes’
is variably used in drafting these overviews. A useful dynamic
overview is maintained by the group of H. Bjornsson at www.epi
geneticmachinery.org (12).
For this review we have defined chromatinopathy genes
based on their ability to chemically modify or remodel chromatin
structure. This essentially encompasses a list of genes whose
corresponding protein products have a catalytic function in
installing post-translational histone modifications and DNA
modifications (writers), removing such modifications (erasers)
or have chromatin remodeling activity (remodelers). The readers
of chromatin structures are confined to proteins that have a
reader domain for binding to specific chromatin modifications
and chromatin architectural proteins. To select these genes,
we first identified all human genes that satisfied these criteria
by querying the Gene Ontology (GO) database (http://amigo.
geneontology.org/amigo/search/ontology; release May 2020)
with the search term ‘chromatin organization’ (GO:0006325).
Chromatin organization is defined as any process that results
in the specification, formation or maintenance of the physical
structure of eukaryotic chromatin and together with its child
terms (Supplementary Material, Table S1) seems to cover all
chromatin modulating processes. In total 771 of 19 858 human
genes in the GO database are classified with the GO term
‘chromatin organization’. This group was complemented by
the selection of 295 genes from the epigenetic machinery
database, which harbors a wider collection of stringently
selected chromatin readers, resulting in a collection of 872
genes (12) (Supplementary Material, Table S2). Next, we selected
all genes for which causative variants have been reported to
cause an NDD, using the SysID database (https://sysid.cmbi.u
mcn.nl/). SysID comprises 1333 verified NDD genes (March 2020)
for which causative monogenic variants have been reported
in multiple unrelated individuals with a neurodevelopmental
phenotype (13). Overlay of the SysID genes with the chromatin
control genes revealed 121 SysID genes with the GO annotation
chromatin organization. In line with previous notions, this
analysis shows that genes with an epigenetic function are
enriched in the list of NDD genes compared to the list containing
all human genes by a factor of 2.33 (P < 0.0001) (8,14), which
is similar to the enrichment of synapse-related genes [1354
genes with GO term synapse, 210 in SysID; enrichment of 2,31
(P < 0.0001)].To be sure we did not miss a major number of
genes implicated in NDDs, we visually inspected the SysID
database, which revealed ADNP, YY1 and RBPJ as additional
genes. Furthermore, a query of other disease gene databases,
such as the Developmental Disorders Genotype-to-Phenotype
database (DDG2P) table from the ‘Deciphering Developmental
Disorders’ project and the AutDB autism database (15,16),
revealed an additional six high-confidence chromatin-related
genes that were still ranked as candidates in SysID: DDB2, DDX11,
GPX4, HDAC4, KMT5B and MORC2, bringing the total overlap to
130 genes (Supplementary Material, Table S3).
The 130 epigenetic NDD genes encompass the writers,
erasers, remodelers and readers. Only 18 genes carry bi-allelic
variants that cause an NDD phenotype. The majority is either
X-linked or has disease-causing variants that manifest in a dom-
inant pattern that often arise by de novo mutation. This indicates
that chromatinopathy genes are highly dosage sensitive. Histone
methyltransferases (HMTs) are particularly abundant amongst
the writers, followed by histone acetyltransferases (HATs), and
other rare chromatin modifiers (ubiquitination, phosphory-
lation, biotinylation, O-GlcNAcylation and DNA methylation).
Members of the superfamily II helicases involved in adenosine
triphosphate (ATP)-dependent nucleosome translocation are
prominent in the group of remodelers. These helicases cover
five conserved protein complexes: (1) SWI/SNF (Switch/Sucrose
Non-Fermentable) [a.k.a. BRG1-associated factors (BAF)], (2)
imitation switch, (3) chromatin helicase DNA binding (CHD),
(4) INO80/SWR1 and (5) ATRX.
Chromatinopathy genes cluster in epigenetic
modules
The functional interactions across chromatinopathy genes pro-
vide a first step to picture how epigenetic dysregulation leads
to neurodevelopmental defects. To uncover possible genotype–
phenotype network associations, hierarchical clustering of func-
tional interactions with the 130 genes was performed using
STRING (17). Using stringent connectivity based on experimental
evidence, several chromatinopathy genes are not clearly con-
nected to others. However, abundant direct interactions between
chromatinopathy genes catch the eye with major epigenetic
regulator complexes such as complex of proteins associated
with Set1 (COMPASS), polycomb recessive complex 2 (PRC2),
nucleosome remodeling deacetylase (NuRD) and BAF complex as
converging hubs in the network. These complexes are connected
to one another by other chromatinopathy proteins, such as β-
catenin (CTNNB1) and transcriptional activators/HAT p300 and
cAMP response element-binding protein (CREB) binding protein
(CREBBP/CBP).
The BAF complex, or the mammalian SWI/SNF complex,
emerged as the strongest hub across chromatinopathy proteins
(18). The complex has the ability to mobilize nucleosomes and
is composed by core ATPase proteins and unique components
dependent on the cell type in which they function. BAF
complexes seem to have a genome-wide control on both
active H3K4me2 and repressive H3K27me3 marks during
late cortical development by directly interacting with the
corresponding demethylases (19). Thus, inactivation of BAF
complexes leads to H3K27me3-linked silencing (via KDM6A/B)
of neuronal differentiation-related genes with concurrent
H3K4me2-mediated activation (via KDM1A) of proliferation-
associated genes via derepression of WNT signaling. Mutations
in genes encoding various subunits of BAF complex often lead
to what is known as SWI/SNF-related intellectual disability
(ID) or BAFopathies, including Coffin–Siris syndrome (CSS),
Nicolaides–Baraitser syndrome and other ID disorders, which
share phenotypic features of developmental delay, ID, coarse
facial features and phalangeal abnormalities (20,21). The
BAFopathies represent a great example of the genetic principle
that mutation of components of the same protein complex or
nodes of the same molecular pathway give rise to disorders
with overlapping phenotypes. A similar genotype–phenotype
network association has been identified for Kleefstra syndrome,
which is caused by loss-of-function mutations of EHMT1,
encoding euchromatic histone methyltransferase 1 (EHMT1),
a transcriptional repressor via mono- and dimethylation of
histone 3 lysine 9 (H3K9me1/2). Exome sequencing of individuals
with a phenotype strongly reminiscent of Kleefstra syndrome
(Kleefstra syndrome spectrum [KSS]) revealed de novo mutations
in several other chromatinopathy genes, including MBD5, KMT2C
and the BAF complex gene SMARCB1 (22). The differential
phenotypes of CSS and KSS associated with SMARCB1 might
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variants in addition to the clinical variability typically observed
for individual chromatinopathy disorders (21,23,24). Physical
and functional interactions amongst the KSS proteins revealed
an EHMT1-associated chromatin-modification module, which is
connected to the BAF, COMPASS and PRC2 complexes (Fig. 1).
Polycomb recessive complex 1 (PRC1) and PRC2 are both
responsible for silencing genes unnecessary for the current
state of the cells through monoubiquitination of H2AK119 and
methylation of H3K27, respectively. PRC2 is a highly conserved
multimeric complex consisting of four core proteins: EZH1/2,
EED, SUZ12 and RBBP4/7, and a variety of accessory proteins
that co-regulate PRC2 activity (25). Pathogenic mutations in
EZH2, SUZ12 and EED are seen in overgrowth syndromes with
variable ID, such as Weaver syndrome and Cohen–Gibson
syndrome (26–28). PRC2 interacts with DNMT3A. Somatic
DNMT3A dominant-negative/loss-of-function mutations that
lead to DNA hypomethylation at PRC2-responsive loci are
frequently seen in hematological disorders. Similar germline
mutations are also encountered in Tatton–Brown–Rahman
syndrome, which is characterized by overgrowth, ID, tall stature,
distinctive facial appearance and in some cases leukemia (29).
Interestingly, DNMT3A gain-of-function mutations in Heyn–
Sproul–Jackson syndrome are associated with hypermethylation
at PRC2 loci and pre- and postnatal growth retardation (30).
Other connections of PRC2 to chromatinopathy proteins
comprise NSD1, underlying another overgrowth disorder (Sotos
syndrome), YY1 (Gabriele–de Vries syndrome) and ATRX (several
X-linked ID disorders).
PRC2 cooperatively interacts also with EHMT1 to exert repres-
sive activity by PRC2-installed H3K27me3 marks. The repres-
sion is countered by the H3K27 demethylase activity of KDM6A
(31,32), which is affected by hemizygous loss-of-function muta-
tions in Kabuki syndrome type 2 (33). KDM6A is an integral regu-
lator of macromolecular complexes called COMPASS that consist
of variable constellations of SET family HMT with H3K4me1/2/3
activity (SETD1A/B and MLL/KMT2 proteins) (34). Germline muta-
tions in all COMPASS methyltransferases have been implicated
in NDDs, which share a range of clinical phenotypes includ-
ing prominent cognitive impairment, behavioral abnormalities
and features of abnormal craniofacial, skeletal and cardiovas-
cular development (22,35–37). Interestingly, KMT2D, which is
mutated in Kabuki syndrome type 1, interacts with KDM6A and
CBP/p300 HAT (Rubinstein–Taybi syndrome) to promote tran-
scriptional activation (38,39). KMT2C was found to be mutated
in a number of KSS patients, which is somewhat surprising as
KMT2C and EHMT1 have opposing activities as transcriptional
activator and repressor, respectively. Many other interactions
between COMPASS and other chromatinopathy proteins have
been uncovered, such as with the chromatin remodeler CHD8,
which activates expression of BRG1-associated BAF complexes
and recruits MLL/KMT2 COMPASS complexes to promote central
nervous system myelination and myelin repair (18,40,41).
Transcriptional convergence in neurogenesis:
WNT signaling
Not surprisingly, epimutations in chromatinopathies are asso-
ciated with transcriptional deregulation of genes that are crit-
ical for proper neurodevelopment as well as genes that are
important for acute neurophysiological processes. Disruption of
genes during neurogenesis is often associated with imbalances
in proliferation and differentiation of neural progenitors cells
(NPCs), giving rise to structural brain anomalies such as micro/
macrocephaly and cortical malformations. Previous integrated
analysis of six exome studies uncovered a network of genes
mutated in autism spectrum disorder (ASD) and ID highlighting
proteins converging on β-catenin as a part of the WNT sig-
naling pathway (41). In support of this, a recent study defined
molecular and functional subclasses within a set of 30 autism-
related genes (in fact better defined as NDD genes) based on
the in vitro neurogenic potency of pluripotent stem cells carry-
ing engineered mutations in these genes (42). This identified a
class of eight genes with mutations associated with increased
proliferation and inhibited neurogenesis (class 1 comprising
chromatinopathy genes ASH1L, ASXL3 KDM5B and KMT2C). The
reduced neurogenesis was strongly correlated with a reduced
response to WNT signaling. Notably, five of the eight class 1
genes are known as regulators of polycomb, which like WNT is
critical for coordinating the balance between NPC proliferation
and differentiation (43–48). PRC2 positively regulates WNT/β-
catenin signaling in various cell types through the silencing of
WNT antagonists, and EZH2 expression maintains NPC prolifer-
ation and is negatively correlated with neuronal differentiation
(49–51). Accordingly, mutations of EZH2 in Weaver syndrome
are associated with overgrowth and macrocephaly. It should
be noted, however, that the study of Cederquist et al. (42) also
uncovered a smaller class of genes with the opposite neurogenic
effects, which did not have an altered WNT response despite
the fact that two chromatinopathy genes from this class, KMT2A
and CHD8, are also regulators of polycomb. Moreover, mutations
in these genes have variable growth defects in patients. This
observation reinforces observations that the neurogenic prop-
erties of WNT and polycomb complex might be dependent on
the specifics of the progenitor cells and the timing in cortical
development (48).
Nevertheless, these exciting data reinforce the notion that
the balance between proliferation and differentiation controlled
by WNT signaling is mirrored by a delicate chromatin-based
balance between activation and repression involving compo-
nents of PRC2 and COMPASS. Previously, also the BAF complex
was shown to control WNT signaling. Loss-of-function muta-
tions affecting individual components in BAFopathies lead to
activation of proliferation-associated genes via derepression of
WNT/β-catenin in various proliferative cell types (52–54). CHD8,
connecting BAF and COMPASS complexes, negatively regulates
β-catenin-targeted gene expression important in cellular prolif-
eration and differentiation (55,56). In Chd8 depleted mice, PRC2
regulation of WNT signaling appears to be the major altered
pathway (57), and accordingly, an overgrowth phenotype with
macrocephaly has been reported in CHD8-related NDD patients
and animal models (28,58–60).
Transcriptional convergence at the synapse in acute
neurophysiological processes
Communication between the synapse and the nucleus in both
directions is critical for neuronal development and plasticity.
Synaptic activity triggers Ca-dependent signaling via signaling
pathways such as PI3K-AKT-mTOR and RAS-MAPK that lead
to activation and repression of genes that control neural con-
nectivity and function. Integration of these activity-dependent
transcriptional processes is mediated by some key transcription
factors, such as CREB, MEF2 and MECP2, and heavily involves
the regulation of chromatin organization. Well-known direct tar-
gets of these transcriptional complexes include immediate early
genes such as c-FOS, ARC and BDNF, and disrupted expression
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Figure 1. Simplified protein–protein interaction network of compiled chromatinopathy genes generated by StringDB (version 11.0, MCL clustering) analysis of
chromatinopathy genes. For clarity, only proteins with interactions are shown. Connecting lines showing medium- and high-confidence experimental interactions
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The deregulated expression appears to be a direct consequence
of the causative mutation in these genes, and not just a sec-
ondary effect of neuronal pathology. Genome-wide expression
studies in animal and cell models of chromatinopathies show an
enrichment of differentially expressed genes that are associated
with synaptic processes (65–69). For example, direct EHMT1 tar-
gets that were inappropriately repressed in the Ehmt1+/− mouse
model for KS were linked to ion channels, synaptic vesicle and
calcium signaling, and include BDNF as an important factor in
the disrupted homeostatic plasticity in these animals (64,70–72).
Epigenetic repressors such as EHMT1 and KDM5C interact with
the RE1 silencing transcription factor (REST) to repress neuronal
genes in extraneuronal tissues, and accordingly, loss of REST
activity leads to upregulation of synaptic proteins, including
SNAP25, Synapsin1, SCN2A, NMDAR1 and BDNF (73–75). In addi-
tion, EHMT1 appears to be a critical regulator of neuronal speci-
fication by regulation of protocadherins, possibly in conjunction
with REST, and olfactory receptors.
Recent work using neuronal knockdown of genes from the
KSS epigenetic module (EHMT1, MBD5, KMT2C and SMARCB1)
identified commonly dysregulated classes of target genes,
mainly involved in regulating neuronal excitability and synaptic
function (76). However, the deregulation of individual genes
from these classes shows differences in line with the specific
activities of these proteins. Thus, knockdown of KMT2C and
SMARCB1 generally leads to downregulation of genes, whereas
EHMT1 knockdown yielded more upregulated than downreg-
ulated genes, including genes encoding proteins required for
ion transport and synaptic transmission. MBD5 knockdown
had more subtle effects on the expression of these genes
and in addition showed a more pronounced deregulation of
cell adhesion and nucleosome assembly proteins. Thus, KSS
target genes converge on neuronal excitability and synaptic
function, albeit in variable patterns for each specific KSS gene.
Despite these differences, the cumulative effect of deregulation
of the synapse-related genes appears to result in a remarkably
similar disruption of intrinsic synaptic properties and neuronal
network activity.
Neurophysiological phenotype convergence
An emerging concept of a common neurophysiological mode-
of-failure is the excitation/inhibition (E/I) imbalance hypothesis,
brought forward by Rubenstein and Merzenich in 2003, which
postulates that excessive excitatory activity relative to inhibitory
ones is a major contributor to autism pathology. This hypothesis
was supported by the high comorbidity of epilepsy and autism
(77). The E/I imbalance hypothesis has since grown into a broader
concept encompassing a large range of perturbations within the
excitation or inhibition neuronal circuits for a broader group of
NDDs (78–80). E/I imbalance might be caused by alterations in
glutamatergic excitatory drive, inhibitory connectivity or a com-
bination thereof. As mentioned, KSS gene-deficient neuronal
networks showed increased neuronal excitability, hyperactive
networks with altered network organization and E/I balance
(76). For all KSS genes, the shift in E/I balance was toward
excitation. For EHMT1, this was associated with reduced num-
ber of inhibitory synapses, whereas for SMARCB1, KMT2C and
MBD5, a reduction of both inhibitory and excitatory synapses
was seen (76).
In Rett syndrome (RTT), the E/I balance can either be shifted
toward excessive excitation or inhibition depending on the brain
area. The importance of a tightly regulated E/I balance is demon-
strated by the observation that knockout of Mecp2 show elevated
parvalbumin (PV) expression together with excessive excitatory
inputs converging onto PV-expressing inhibitory neurons in the
somatosensory and motor cortex associated with the sensori-
motor defects (81). Distinct types of inhibitory neurons appear
to contribute differently to phenotypic manifestations. Loss of
MECP2 in PV+ neurons gives rise to progressive motor, sensory,
memory and social deficits, whereas those lacking MeCP2 in
somatostatin-positive (SOM+) neurons leads to seizures and
stereotypic behavior. A similar observation was made for Arid1b
haploinsufficiency, which in PV+ neurons contributed to social
and emotional impairments, whereas Mecp2 loss in SOM+ neu-
rons caused stereotypies as well as learning and memory dys-
function (54,82). An interesting observation is that the overall
network imbalance contributing to the phenotypic regression in
RTT involves N-methyl-D-aspartate receptor (NMDAR) dysfunc-
tion. Indeed, genetic deletion of the NMDAR subunit GluN2A
in mice or NMDAR inhibition by ketamine prevented RTT phe-
notypes (83,84). Similarly, EHMT1 deficiency in both mice- and
human-induced pluripotent stem cells-derived cortical excita-
tory neurons reduced the deposition of repressive H3K9me2
marks at the GRIN1 promoter and, encoding an NMDAR sub-
unit, leading to increased GRIN1 expression and altered NMDAR
function (85). Based on these preclinical observations, modula-
tion of NMDAR is hypothesized to be a potential symptomatic
treatment for several chromatinopathies, and clinical trials with
ketamine are currently ongoing for RTT and Helsmoortel–Van
der Aa syndrome.
Convergence as a target for therapy
Each of the individual chromatinopathy disorders has an
extremely low prevalence, and therefore these disorders are
not very attractive for developing gene-based interventions.
However, the patterns of convergence that we have described
for chromatinopathies might offer opportunities for developing
therapeutic strategies that are applicable to a wider group
of disorders. Such interventions can be directed at any level
in the convergence pyramid (Fig. 2): protein complexes, gene
expression, signaling pathways and cellular processes such as
synaptic activity. This idea is not restricted to chromatinopathies
and convergence can be seen for other NDDs as well. For
example, disrupted mTor signaling is well known to be affected
in a large number of different NDDs and is downstream of major
signaling pathways, PI3K-AKT and RAS-MAPK, which are often
directly affected by genetic variants in many rare syndromes (86).
Consequently, rapamycin and other mTor modulators are being
used in trials for ID and ASD disorders. Similarly, regulators
of E/I balance and NMDAR antagonist like ketamine might be
considered for treatment of several chromatinopathies. The
downside of such generic interventions is that the expected
effects are likely restricted to specific symptomatic features. Yet,
very often these features are comorbid across a large number
of NDDs, regardless of the classical categorical classification
such as ID, ASD, schizophrenia and others. Therefore, such
symptomatic interventions might be attractive to consider for
many genetically distinct disorders. It is of eminent importance
to further strengthen the patterns of convergence to increase
knowledge about the underlying biological mechanisms in order
to develop rational strategies for intervention applicable to larger
groups of disorders caused by different genetic defects.
Supplementary Material
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Figure 2. Schematic representation of convergence of chromatinopathies. Individual chromatinopathy genes encode proteins that interact with each other in chromatin
remodeling. These interactions cluster in chromatin remodeling complexes such as the BAF, PRC2 and COMPASS complexes, which then affect the transcription of their
target genes. Aberrant transcription level of various genes in different chromatinopathies leads to commonly disrupted molecular and cellular processes, such as WNT
signaling and genes involved in acute synaptic function. Disrupted WNT signaling affects proliferation of stem cells and the process of neurogenesis, which can lead
to anomalies in brain development such as micro- and macrocephaly. Synaptic function and activity is an important process in brain circuits development. Imbalance
of excitation and inhibitory (E/I) has emerged as a common neurophysiological mode-of-failure in ASD, ID and NDDs in general. Combination of disruption of multiple
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